Generex Awarded New Pain Relief Patents
Company Expands Patent Portfolio in Mexico and New Zealand
Generex Biotechnology Corporation announced that it has received two new patents, one in Mexico (issued by the Mexican Institute of Industrial Property), the other in New Zealand (issued by the Intellectual Property Office of New Zealand).
The patents share the title "Pharmaceutical Compositions for Buccal Delivery of Pain Relief Medications" and contain claims to a pharmaceutical composition for pain relief containing a narcotic analgesic in micellar form.
"We are pleased that our patent portfolio is expanding to include the pain relief application," said Rose Perri, the Company's Chief Operating Officer. "As we continue the pivotal Phase III studies of our flagship product, Generex Oral-lynT, we seek additional applications for our proprietary drug platform technology."
Generex currently holds an aggregate of 130 patents worldwide (21 of which are United States patents) and has an aggregate of 132 patent applications pending in various jurisdictions.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.